CARBIOS
Regulatory News:
CARBIOS (Euronext Growth Paris: ALCRB) (Paris:ALCRB), a company pioneering new bio-industrial solutions to reinvent the lifecycle of plastic and textile polymers, announces the publication of an article in the prestigious scientific journal Nature, entitled “ An engineered PET-depolymerase to break down and recycle plastic bottles” . The article is co-authored by scientists at Carbios and at the Company’s renowned academic partner, the Toulouse Biotechnology Institute 1 (TBI).
The article describes the development of a novel enzyme, which can biologically depolymerize all polyethylene terephthalate (PET) plastic waste, followed by an extremely efficient recycling into new bottles. PET is the most common thermoplastic polymer and is used to manufacture bottles, polyester clothing fibers, food containers, and various thermoformed packaging and components. Carbios’ recycling process, the first of its kind, initiates a real transition to a circular economy and can better prevent plastic pollution from harming our oceans and planet. This innovative technology also paves the way for recycling PET fibers, another major challenge in guaranteeing a clean and protected environment for future generations.
Prof. Alain Marty, Carbios’ Chief Scientific Officer and co-author of the Nature article says: "I am very proud that Nature, one of the most highly respected scientific journals in the world, has validated the quality of the research led by Carbios and TBI laboratory scientists in developing a PET recycling enzyme and a revolutionary process. The results obtained confirm the industrial and commercial potential of the Company’s proprietary process, which will be tested in 2021 in our demonstration plant in the heart of the French Chemical Valley, near Lyon."
Sophie Duquesne, INRAE Researcher: “For any researcher, seeing its work recognized by the prestigious journal Nature is a true achievement. I am very proud of the work accomplished by the researchers at TBI and Carbios, whose collaborative efforts have led to the development of a sustainable solution to the end of life of plastics.”
Dr. Saleh Jabarin, Distinguished Professor at The University of Toledo, Ohio and a member of Carbios’ Scientific Committee: “It's a real breakthrough in the recycling and manufacturing of PET. Thanks to the innovative technology developed by Carbios, the PET industry will become truly circular, which is the goal for all players in this industry, especially brand-owners, PET producers and our civilization as a whole.”
Bertrand Piccard, Founder and President of the Solar Impulse Foundation: “I am very pleased that the scientific community recognizes one of the solutions labelled by the Solar Impulse Foundation as a financially profitable solution to protect the environment. The use of such technology is as logical as it is ecological!”
Nature, the highest Impact Factor scientific journal, recognizes the ground-breaking quality of the enzymatic engineering research being done by Carbios and TBI, that is paving the way to virtuous management of plastic waste. “Carbios is the first company to successfully combine the two scientific worlds of enzymology and plastics” , as Dr. Philippe Pouletty, CEO of Truffle Capital and Co-founder of Carbios , comments.
By leveraging many years of experience with a world-renowned team, Carbios and TBI are proud to have been able to increase the degradation yield of PET waste to 90% in 10 hours, a significant upswing from the initial degradation yield of 1% after several weeks. This paradigm shift in how effectively PET can be recycled, is leading toward a future circular economy technology applicable to all PET waste, which Carbios is proud to be spearheading.
To read the article in Nature, please find the link here:
https://www.nature.com/articles/s41586-020-2149-4
About Carbios:
Carbios is a green chemistry company whose innovations help address the environmental and sustainable development challenges facing manufacturers. Since its creation in 2011 by Truffle Capital , the Company has developed, through biotechnology, two industrial processes that revolutionize the biodegradation and recycling of polymers. These world-first innovations, made possible with the support of Bpifrance (THANAPLAST™ project), enable to optimize the performance and lifecycle of plastics and textiles by exploiting the properties of highly specific enzymes.
Carbios' economic development model is based on the industrialization and commercialization of its products and/or enzymes, technologies and bioprocesses through license concessions directly or through joint ventures to major industrial players or sectors concerned by the Company's innovations. As such, Carbios created the joint venture Carbiolice in September 2016, in partnership with Limagrain Ingredients and the SPI fund operated by Bpifrance. This company, of which Carbios has majority control, will exploit the first technology licensed by Carbios by producing enzymatic granules for the production of biodegradable and biobased plastics.
Carbios benefits from the qualification "Innovative Company" of Bpifrance allowing the eligibility of the Company's securities for the investment of Mutual Funds Placement in Innovation (FCPI). For more information, please visit: www.carbios.fr
Carbios is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates.
About Truffle Capital:
Established in 2001, Truffle Capital is a leading European Venture Capital company, specializing in breakthrough life sciences and FinTech technologies. Truffle Capital supports the creation and growth of young innovative companies capable of becoming tomorrow’s leaders. Headed by Patrick Kron, chairman, alongside cofounders and co-CEOs Philippe Pouletty, MD, and Bernard-Louis Roques, Truffle Capital has raised over €1.1 billion and has supported over 75 companies in the digital technology and life sciences sectors.
For more information: www.truffle.com – Twitter: @trufflecapital
This press release does not constitute and cannot be regarded as constituting an offer to the public, an offer to sell or a subscription offer or as a solicitation to solicit a buy or sell order in any country.
Translation for information purposes only. In case of discrepancy between the French and the English version of this press release, the French version shall prevail.
1 : A mixed research unit INSA Toulouse, INRAE, CNRS.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200408005484/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Most Delivered Light-Entry Jet Cessna Citation M2 Gen2 With Garmin Autothrottles Enters Into Service, Bringing Greater Control and Precision to Pilots14.1.2026 20:30:00 CET | Press release
The Cessna Citation M2 Gen2 with Garmin Autothrottles recently entered into service. Certified by the Federal Aviation Administration in October 2025, the integration of Garmin’s Autothrottle system in the Citation M2 Gen2 further supports the most delivered light-entry jet’s capabilities by bringing greater control and precision to pilots. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114646844/en/ Most delivered light-entry jet Cessna Citation M2 Gen2 with Garmin Autothrottles enters into service, bringing greater control and precision to pilots (Photo Credit: Textron Aviation). The Cessna Citation M2 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “We continue to invest in our products to provide customers with the best aviation experience in the world," said Lannie O’Bannion, senior vice president, Sales & Marketing. “The M2 Gen2 leads its segment as the most delivered
TwentyTwo Real Estate and Farallon Capital Complete €761 Million Investment in Isemia, a €1.2bn Healthcare Real Estate Company Created With emeis14.1.2026 18:30:00 CET | Press release
TwentyTwo Real Estate, an independent European real estate investment and management firm, announces the completion, alongside Farallon Capital, of a €761 million investment that led to the creation of Isemia (www.isemiabyemeis.com), a leading healthcare real estate company holding a €1.2 billion portfolio of assets operated by emeis. The transaction represents a significant milestone in TwentyTwo Real Estate’s long-term investment strategy focused on healthcare and operational living real estate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114262830/en/ Fachklinik Schömberg Isemia comprises 68 high-quality assets across France, Germany and Spain, with a balanced mix of nursing homes (48%) and clinics (52%). The portfolio benefits from strong fundamentals and resilient operating performance. All properties will continue to be operated by emeis under long-term lease agreements, ensuring continuity of care for residents
AI’s Water Demand to Surge Nearly 130% by 2050 – New Research Shows How to Build a Water-Secure AI Economy14.1.2026 16:00:00 CET | Press release
Analysis finds AI could add 30 trillion liters of annual water demand, but targeted reuse and digital infrastructure investments can substantially offset demand and protect communities The rapid global expansion of artificial intelligence is set to drive a 129% increase in water demand across the AI value chain by 2050, according to new research by Xylem (NYSE: XYL) and Global Water Intelligence (GWI). Watering the New Economy: Managing the Impacts of the AI Revolution provides the most comprehensive assessment to date of how AI is reshaping global water use. It also highlights practical ways to meet that demand while strengthening water security for communities. Spending on AI is forecast to approach $2 trillion in 2026,1 accelerating infrastructure build-out worldwide. By the middle of the century, this expansion is projected to add 30 trillion liters of water demand, annually, fueled by a surge in power generation (~54% of the increase), semiconductor fabrication (~42%), and data ce
ACCELQ Crowned Leader and Customer Favorite in The Forrester Wave™ for Autonomous Testing Platforms14.1.2026 16:00:00 CET | Press release
Agentic Test Automation Pioneer Caps Record-Breaking Year of Growth and "AI-Based Engineering Solution of the Year" Honors Forrester has named ACCELQ a Leader in The Forrester Wave™: Autonomous Testing Platforms, Q4 2025. This marks the third consecutive Wave in which ACCELQ has been recognized as a Leader. Notably, this evaluation placed strong emphasis on generative AI innovation and real-world customer adoption. ACCELQ received the highest scores for both capabilities and vision and was the only platform to be recognized as a Customer Favorite, earning a "double halo" for exceptional customer endorsement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113112861/en/ ACCELQ recognized as a Leader and Customer Favorite in The Forrester Wave™️: Autonomous Testing Platforms, Q4 2025, validating its agentic, GenAI-embedded testing vision. According to the Forrester report, ACCELQ received the highest score among all evaluate
Primient to Acquire Full Ownership of Primient Covation, LLC14.1.2026 16:00:00 CET | Press release
Primient, a global leader in biomanufacturing, announced today it has agreed to purchase the remaining ownership interest in Primient Covation, LLC (“Primient Covation”), establishing Primient as the sole owner of the company and marking an exciting new chapter in Primient’s growth in the bioeconomy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114344080/en/ This acquisition is the next step of Primient’s strategy to strengthen Primient’s leadership position in biomanufacturing and builds upon recent announcements, including Primient’s partnership with Sustainea and the creation of the iPROOF venture. Primient Covation stands as a leading force in the U.S. biomanufacturing sector, distinguished by its broad range of biomanufacturing and fermentation expertise. The company was founded in 2000 to supply a variety of end markets, including cosmetics and personal care, textiles, fashion, coatings, functional fluids, and oth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
